A replication study of the association between the IL12B promoter allele CTCTAA and susceptibility to cerebral malaria in Thai population by Naka, Izumi et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Malaria Journal
Open Access Research
A replication study of the association between the IL12B promoter 
allele CTCTAA and susceptibility to cerebral malaria in Thai 
population
Izumi Naka1, Jintana Patarapotikul2, Katsushi Tokunaga3, 
Hathairad Hananantachai2, Naoyuki Tsuchiya1 and Jun Ohashi*1
Address: 1Doctoral Program in Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, 
Japan, 2Department of Microbiology & Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand and 3Department of 
Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Email: Izumi Naka - izumin-tky@umin.ac.jp; Jintana Patarapotikul - tmjpt@mahidol.ac.th; Katsushi Tokunaga - tokunaga@m.u-tokyo.ac.jp; 
Hathairad Hananantachai - tmhhn@mahidol.ac.th; Naoyuki Tsuchiya - tsuchiya@md.tsukuba.ac.jp; Jun Ohashi* - juno-tky@umin.ac.jp
* Corresponding author    
Abstract
Background: Interleukin-12 (IL-12), a heterodimeric cytokine composed of p35 and p40 subunits,
has been thought to play an important role in the pathogenesis of malaria. The IL-12p40 subunit is
encoded by the IL12B gene. An IL12B promoter allele, CTCTAA, at rs17860508 has been reported
to be associated with susceptibility to cerebral malaria in African populations. However, this
association has not so far been replicated in non-African populations.
Methods: To examine whether the CTCTAA allele is associated with susceptibility to cerebral
malaria in Asian populations, 303 Thai patients with Plasmodium falciparum malaria (109 cerebral
malaria and 194 mild malaria patients) were genotyped for rs17860508 by PCR-direct sequencing.
Results:  The CTCTAA allele showed a significant association with susceptibility to cerebral
malaria in the Thai population (allelic OR = 1.37; one sided P-value = 0.030).
Conclusions:  The existence of a significant association between the CTCTAA allele and
susceptibility to cerebral malaria was confirmed in Southeast Asian population, which was
previously reported in African populations.
Background
Cerebral malaria, a severe form of Plasmodium falciparum
malaria, causes the vast majority of deaths related to P. fal-
ciparum  infection. Although the pathophysiology of
severe malaria (including cerebral malaria) is not fully
understood, significant differences in serum or plasma
concentrations of various cytokines have been observed
between severe and mild malaria patients. The levels of
interleukin-12 (IL-12) are significantly lower in patients
with severe malaria in comparison to those with mild
malaria [1,2]. In animal models of malaria, IL-12 has
been shown to have a protective role [3-5], although path-
ogenic effects of IL-12 in malaria have also been reported
[5]. Considering the fact that only some malaria patients
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develop cerebral malaria, human genetic polymorphisms
may play an important role in determining the severity of
the disease. In this context, genes encoding IL-12 are
attractive candidates for determining the susceptibility to
cerebral malaria.
Interleukin-12 (IL-12) is a heterodimeric cytokine formed
by a 35-kDa light chain (p35 or IL-12a) and a 40-kDa
heavy chain (p40 or IL-12b). The IL-12p40 heavy chain is
encoded by the IL12B gene. The IL12B has a functional
polymorphism, CTCTAA/GC (rs17860508), with a 4 bp
difference between the two alleles in the promoter region.
The CTCTAA/GC polymorphism has been shown to affect
the gene expression and the production of cytokines and
nitric oxide [6-9]. The homozygotes of CTCTAA were
reported to be associated with increased mortality in Tan-
zanian children with cerebral malaria [9]. Recently, the
strong association of CTCTAA with the risk of cerebral
malaria was also observed in family-based association
studies in Mali [10]. However, this association has not yet
been examined in non-African populations, such as
Southeast Asians. The purpose of this study is to assess
whether the IL12B promoter allele, CTCTAA, is associated
with susceptibility to cerebral malaria in Thais.
Methods
Subjects
A total of 303 adult patients with P. falciparum malaria
(109 cerebral malaria and 194 mild malaria patients) liv-
ing in northwest Thailand were analysed in this study. All
patients underwent treatment at the Hospital for Tropical
Diseases, Faculty of Tropical Medicine, Mahidol Univer-
sity. Malarial infection by P. falciparum was confirmed in
all patients by a positive blood smear for the asexual form
of P. falciparum. Clinical manifestations of malaria were
classified according to the definitions and associated crite-
ria by the World Health Organization. Cerebral malaria
was defined as unrousable coma, a positive result in tests
for the presence of an asexual form of P. falciparum, and
exclusion of other causes of coma. Mild malaria was
defined as having a positive blood smear and fever with-
out other causes of infection and no signs indicating
severe malaria such as high parasitaemia (> 100,000 par-
asites/ml), hypoglycemia (glucose level < 22 nmol/L),
severe anaemia (haematocrit < 20% or hemoglobin level
< 7.0 g/dl) or increased serum level of creatinine (> 3.0
mg/dl). All individuals were 13 years old or older, and the
mean ages of patients with mild malaria and cerebral
malaria patients were 25.5 and 28.6 respectively. This
study was approved by the institutional review board of
the Faculty of Tropical Medicine, Mahidol University, and
the Research Ethics Committee of the Graduate School of
Comprehensive Human Sciences, University of Tsukuba.
Informed consent was obtained from all patients.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using a QIAamp Blood Kit (Qiagen, Hilden, Ger-
many). The IL12B promoter polymorphism, rs17860508,
was genotyped by PCR-direct sequencing with an ABI
PRISMTM 3100 Genetic Analyzer (Perkin-Elmer Applied
Biosystems). PCR was performed using a primer set: a 5'
primer IL12B-proF: 5'-GGATCAGGGTCTGGATTGTG-3'
and a 3' primer IL12B-proR: 5'-GGCTGATGCTTGGA-
GATTGT-3'. The amplification condition consisted of an
initial denaturation at 96°C for 10 min, followed by 35
cycles of denaturation at 96°C for 30 sec, annealing at
60°C for 30 sec, and extension at 72°C for 1 min using a
thermal cycler (GeneAmp PCR system 9700; Perkin-Elmer
Applied Biosystems).
Statistical analysis
The differences in genotype and allele frequencies
between the patients with cerebral and mild malaria were
examined by the Cochran-Armitage test for trend and chi-
square test, respectively. The P-values for association were
calculated by a one-sided test to avoid a false negative
because the CTCTAA allele had been previously reported
to be associated with both susceptibility to and mortality
from cerebral malaria. The deviation from Hardy-Wein-
berg equilibrium (HWE) for each malaria group was
assessed by a chi-square test. A P-value of less than 0.05
was regarded as statistically significant in this study.
Results and Discussion
The genotype of rs17860508 was analysed in 303 Thai
patients with malaria (Table 1). The genotype frequency
did not deviate from HWE in each malaria group (P-value
> 0.05). Consistent with observations in African popula-
tions, the CTCTAA allele showed a significant association
with susceptibility to cerebral malaria in the Thai popula-
tion (allelic OR = 1.37; one sided P-value = 0.030). The
Cochran-Armitage trend test for the genotype frequency
also established the association between the CTCTAA
allele and cerebral malaria (P-value = 0.038). Although a
previous study demonstrated that the CTCTAA/GC heter-
ozygotes increased the risk of cerebral malaria [10], such
a tendency was not observed in the present study. In
Thais, the risk of cerebral malaria seems to correlate with
the number of copies of the CTCTAA allele (i.e., 0, 1, or 2)
in malaria patients. This may be the ethnic difference
between African and Asian.
The significant association of the CTCTAA allele with sus-
ceptibility to cerebral malaria was found both in children
living in Mali [10] and in Thai adults (this study). In areas
of low endemicity, where the immunity is low, severe
infection occurs in all age groups including adults as in
the studied population. Since the endemicity differsMalaria Journal 2009, 8:290 http://www.malariajournal.com/content/8/1/290
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between Africa and Southeast Asia, it should not readily
be concluded that the present association of the CTCTAA
allele with susceptibility to cerebral malaria is independ-
ent of age. To evaluate this, further association studies are
required to be conducted in Thai children.
The present results suggest that the IL12B promoter poly-
morphism at rs17860508 plays an important role in
determining the onset of cerebral malaria, although the
role of IL-12 in malaria infection remains to be studied.
Conclusions
A significant association of the IL12B promoter CTCTAA
allele with cerebral malaria was replicated in a Thai popu-
lation.
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Table 1: Genotype and allele frequencies of the IL12B promoter polymorphism in Thai malaria patients.
Frequency P-value
Cerebral malaria
(n = 109)
Mild malaria
(n = 194)
Genotype:
CTCTAA/CTCTAA 34 (0.312) 49 (0.252) 0.038a
CTCTAA/GC 51 (0.468) 83 (0.428)
GC/GC 24 (0.220) 62 (0.320)
Allele:
CTCTAA 119 (0.546) 181 (0.466) 0.030b
GC 99 (0.454) 207 (0.534)
aOne-sided P-value was calculated based on the result from the Cochran-Armitage test for trend.
bOne-sided P-value was calculated based on the result from chi-square test.